Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Mevidalen hydroxybenzoate by Eli Lilly and Co for Alzheimer's Disease: Likelihood of Approval
Mevidalen hydroxybenzoate is under clinical development by Eli Lilly and Co and currently in Phase II for Alzheimer's Disease. According...